{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 165 of 169', 'Section number and', 'Description of change', 'Brief rationale', 'name', 'This report Complaint forms should', 'contain a detailed description of the', 'defect, issue, or malfunction device', 'deficiency, including whether it the', 'malfunction led to an AE. (S)AEs', 'which occur due to a defect or issue', 'with the IMP or due to a device', 'deficiency will be reported by the', 'investigator as described in Sections', '11.2 and 11.3.', 'Section 10.1', 'Investigator assessments (performed', 'Clarification that SCORAD', 'Overview', 'only by adequately trained', 'component C (completed by the', 'investigators; the same investigator', 'subject) will be completed prior to', 'should perform all the evaluations for', 'any investigator assessments.', 'a given subject throughout the entire', 'trial period) in the following order:', '1. SCORAD component C,', 'then component A and B.', '2. IGA.', '3. EASI.', 'Section 10.3.1.1', 'Clinical signs and morphological', 'Added following a request from', \"Investigator's Global\", 'descriptors have been added to the', 'the FDA.', 'Assessment', 'IGA scale in Panel 10.', 'Section 10.3.1.2', 'Footnote added to Panel 12 on the', 'Clarification that the EASI', 'Eczema Area and', 'EASI severity score scale:', 'severity score scale also includes', 'Severity Index', 'Half-points (0.5; 1.5; 2.5) may also', 'half-points (in alignment with the', 'be used.', 'eCRF and the trial manual).', 'Sections 10.3.2.1', 'All 12 questionnaires are provided in', 'Clarification on where', 'Eczema related Sleep', 'the investigator trial file and not in a', 'questionnaires are filed.', 'numeric rating scale', 'trial manual.', 'to 10.3.2.12', 'Treatment', 'Satisfaction', 'Questionnaire for', 'Medicine', 'Section 10.4.5', 'The central laboratory will provide', 'Clarification regarding the units of', 'Laboratory testing', 'results in conventional units to trial', 'the results from the clinical', 'sites in the US and in SI units to', 'laboratory assessments provided', 'trial sites in Europe and Asia; the', 'to the trial sites across regions.', 'trial sites in the units preferred by the', 'Clarification that results', 'trial sites while the results that are', 'transferred to the trial database', 'transferred to the trial database will', 'will be in both conventional and', 'always be in conventional and SI', 'SI units.', 'units.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 166 of 169', 'Section number and', 'Description of change', 'Brief rationale', 'name', 'Section 10.4.7', 'Samples will be retained for as long', 'Clarification regarding storage of', 'Anti-drug antibodies', 'as the quality of the material', 'ADA samples.', 'measurements', 'permits evaluation but for no', 'longer than 15 years after', 'marketing authorisation.', 'Section 10.5.1.2', 'To minimise the variation between', 'The RNA-based method is more', 'Staphylococcus', 'trial sites, a traditional culture based', 'reliable than the culture-based', 'aureus colonisation', 'non quantitative method for', 'method when swabs have been', 'determining S. aureus colonisation', 'frozen.', 'will be determined usedusing an', 'RNA-based method (quantitative', 'real-time polymerase chain', 'reaction).', 'Section 10.6', 'Total volume of blood to be', '2 blood samples (PK and anti-drug', 'Estimate of total', 'withdrawn has been changed from', 'antibodies) have been added at', 'blood volume', '420 mL to 435 mL', 'Week 4', 'collected', 'Section 11.4.1', 'Pregnant subjects must permanently', 'Alignment between Sections 9.8.1', 'Pregnancy', 'discontinue from the trial IMP (see', 'and 11.4.1.', 'Section 9.8.1).', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}